Publications, Pharmaceutical

Demonstrating bioequivalence for generic fluticasone propionate OINDPs

Optimal strategies for demonstrating bioequivalence for commonly used inhaled drugs are highly relevant to the cost-effective development of generics.

This paper considers the use of pharmacokinetics in the demonstration of the bioequivalence of fluticasone propionate inhalation products, without the need for comparative clinical endpoint studies. Compartmental and non-compartmental pharmacokinetic analyses for three alternative fluticasone dry powder inhaler formulations are examined. These data showed good agreement with formulation characteristics measured using in vitro methods and highlight the potential to use pharmacokinetic studies to assess the dose accessible to the lungs, regional deposition, and pulmonary residence time. The work illustrates how batch-to-batch differences in adjuvant or excipient properties influence pharmacokinetics, providing helpful guidance for those developing generic products.

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 19
Back To Top